



Lytix Biopharma to Present Final Phase II ATLAS-IT-05 Data at the AACR Annual Meeting 2026

Final results from the ATLAS-IT-05 study of ruxotemotide (LTX-315) in combination with pembrolizumab to be presented at AACR 2026

Oslo, Norway, March 18, 2026: Lytix Biopharma (“Lytix” or the “Company”), a clinical-stage immuno-oncology company developing novel intratumoral cancer therapies, today announced that data from its Phase II ATLAS-IT-05 study evaluating ruxotemotide (LTX-315) in combination with pembrolizumab have been selected for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 20–24, 2026 in San Diego, California.

The presentation will highlight final results from the completed Phase II ATLAS-IT-05 study, which evaluated intratumoral ruxotemotide in combination with pembrolizumab in patients with unresectable advanced or metastatic melanoma who have progressed following treatment with anti-PD-1 or anti-PD-L1 therapies.

“We are pleased that the AACR scientific committee has selected the ATLAS-IT-05 study for presentation at this year’s meeting,” said Øystein Rekdal, Chief Executive Officer of Lytix Biopharma. “These results further support the potential of ruxotemotide to induce anti-tumor immune responses in patients with advanced melanoma who have limited treatment options following checkpoint inhibitor therapy.”

Poster Presentation Details:

- **Title:** Intratumoral ruxotemotide (LTX-315) in combination with pembrolizumab in patients with unresectable advanced melanoma refractory to PD-1/PD-L1 therapy: Final results from the ATLAS-IT-05 study
- **Session Title:** Clinical Research – Combination Immunotherapies
- **Session Date and Time:** April 20, 2026; 2:00 PM – 5:00 PM
- **Location:** Poster Section 43, Board #25
- **Poster Number:** 3810

The data will be presented by Dr. Adi Diab of Cleveland Clinic, principal investigator of the study and a recognized expert in melanoma immunotherapy.

Following the AACR Annual Meeting, a copy of the poster will be made available on the Company’s website.

About Ruxotemotide (LTX-315)

Ruxotemotide (LTX-315) is a first-in-class oncolytic peptide designed for intratumoral administration. The molecule disrupts tumor cells locally, leading to the release of

tumor antigens and danger-associated molecular signals that may activate systemic anti-tumor immune responses. This mechanism has the potential to convert immunologically “cold” tumors into “hot” tumors and enhance responses to checkpoint inhibitor therapies.

About Lytix Biopharma

Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with a highly differentiated oncolytic molecule platform based on world-leading research in host-defense peptide-derived molecules. Lytix Biopharma’s lead product, ruxotemitide (formerly LTX-315), is a first-in-class oncolytic molecule representing a new approach to maintaining durable anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that work across multiple cancer indications and treatment settings, both as mono- and combination therapy. Lytix is listed on Euronext Growth Oslo under the ticker LYTIX.